View Older Stories View More Recent Stories
-
Vertex (VRTX) PT Lowered to $460 at Truist Securities
-
Vertex (VRTX) PT Raised to $430 at Scotiabank
-
Vertex (VRTX) PT Lowered to $500 at JPMorgan
-
Vertex Pharma (VRTX) Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
-
Vertex Pharma (VRTX) Announces U.S. FDA Approval for TRIKAFTA to Include Additional Non-F508del TRIKAFTA-Responsive Variants
-
Vertex (VRTX) PT Lowered to $520 at BMO Capital; 'Detour Not a Breakdown'
-
Vertex (VRTX) PT Lowered to $535 at H.C. Wainwright
-
Bernstein on Vertex (VRTX) Post LRS miss: 'Can DPN (and the Stock) Still Work?'; PT Lowered
-
Evercore ISI on Vertex (VRTX): 'we see upside from here in 2025'
-
4 themes and 4 key biotech stocks for 2025: Jefferies
-
Oppenheimer Downgrades Vertex (VRTX) to Perform
-
Vertex (VRTX) PT Lowered to $522 at BofA Securities
-
Goldman Sachs Reiterates Buy Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Reports Results From Phase 2 Study of Suzetrigine
-
Jefferies Upgrades Vertex (VRTX) to Buy
-
BMO Capital: Five Key BioPharma Catalysts Through Year-End '24
-
Here are the key catalysts for 3 US biotech stocks into year end
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
BofA on Vertex Pharma (VRTX): 'At risk for a double top'
-
Citi Starts Vertex (VRTX) at Buy
-
Oppenheimer Reiterates Outperform Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Raised to $451 at RBC Capital
-
Vertex Pharma (VRTX) Tops Q3 EPS by 30c; raises guidance
-
Vertex Pharma (VRTX) November 11 weekly option implied volatility into quarter results
-
Vertex Pharma (VRTX) November 11 weekly 475 straddle priced into quarter results
-
Vertex Pharma (VRTX) Provides Updates on Multiple Kidney Programs
-
Canaccord Genuity Reiterates Sell Rating on Vertex (VRTX)
-
BMO Capital Reiterates Outperform Rating on Vertex (VRTX)
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Goldman Sachs Reiterates Buy Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor
-
Raymond James Resumes Vertex (VRTX) at Market Perform
-
Vertex (VRTX) PT Raised to $437 at RBC Capital
-
Vertex (VRTX) PT Lowered to $518 at Wolfe Research
-
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
-
Vertex Pharma (VRTX) Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA
-
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing - Bloomberg
-
Vertex (VRTX) PT Raised to $550 at Oppenheimer
-
Vertex (VRTX) PT Raised to $576 at Wolfe Research
-
Barclays Downgrades Vertex (VRTX) to Equalweight
-
Vertex (VRTX) PT Raised to $535 at Piper Sandler
-
Vertex (VRTX) PT Raised to $600 at H.C. Wainwright
-
Vertex (VRTX) PT Raised to $515 at Evercore ISI
-
Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
-
Vertex (VRTX) PT Raised to $376 at Canaccord Genuity
-
Vertex Pharma (VRTX) Announces FDA Acceptance of NDA for Suzetrigine
-
Vertex (VRTX) PT Raised to $500 at TD Cowen
-
10 policies if Trump wins and stock implications: Jefferies
-
Vertex (VRTX) PT Raised to $500 at H.C. Wainwright
-
Vertex Pharma (VRTX) Enters New Extension and Expansion of Drug Discovery Collaboration with Genomics

